DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test the hypothesis that DYME is safe and effective
as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining
the anterior capsule. Secondary objectives are to compare the safety and effectiveness of
DYME to that of a smaller dose of the same API.